IDEAYA Biosciences, Inc. (IDYA) › Cash & EquivalentsIDEAYA Biosciences, Inc. (IDYA) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2017: $5.96M2018: $20.50M2019: $34.07M2020: $72.04M2021: $92.05M2022: $68.63M2023: $157.02M2024: $84.38M2025: $112.83M$112.83M2017Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$112.83M+33.7%2024$84.38M-46.3%2023$157.02M+128.8%2022$68.63M-25.4%2021$92.05M+27.8%2020$72.04M+111.5%2019$34.07M+66.1%2018$20.50M+244.0%2017$5.96M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share